Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically ...
Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
− Based on data from prospective Phase 3 LIGHTHOUSE and SPOTLIGHT studies in newly diagnosed and recurrent prostate cancer – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth ...
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and ...
From the foods men eat to how surgery is planned and public awareness unfolds, new research presented at the American Urological Association (AUA) Annual Meeting in Washington, DC, shows prostate ...
Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results